136 related articles for article (PubMed ID: 7576964)
21. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.
Poremba C; Hero B; Goertz HG; Scheel C; Wai D; Schaefer KL; Christiansen H; Berthold F; Juergens H; Boecker W; Dockhorn-Dworniczak B
Klin Padiatr; 2001; 213(4):186-90. PubMed ID: 11528552
[TBL] [Abstract][Full Text] [Related]
22. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
23. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
24. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
25. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
26. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
27. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.
Vega FM; Colmenero-Repiso A; Gómez-Muñoz MA; Rodríguez-Prieto I; Aguilar-Morante D; Ramírez G; Márquez C; Cabello R; Pardal R
EBioMedicine; 2019 Nov; 49():82-95. PubMed ID: 31685444
[TBL] [Abstract][Full Text] [Related]
28. [Expression of CD44-standard in 182 primary neuroblastomas].
Christiansen H; Terpe HJ; Gonzales M; Wenderhold S; Berthold F; Lampert F
Klin Padiatr; 1995; 207(4):219-21. PubMed ID: 7564156
[TBL] [Abstract][Full Text] [Related]
29. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
30. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
31. Nucleolin expression has prognostic value in neuroblastoma patients.
Cangelosi D; Brignole C; Bensa V; Tamma R; Malaguti F; Carlini B; Giusto E; Calarco E; Perri P; Ribatti D; Fonseca NA; Moreira JN; Eva A; Amoroso L; Conte M; Garaventa A; Sementa AR; Corrias MV; Ponzoni M; Pastorino F
EBioMedicine; 2022 Nov; 85():104300. PubMed ID: 36209521
[TBL] [Abstract][Full Text] [Related]
32. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
[TBL] [Abstract][Full Text] [Related]
34. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
[TBL] [Abstract][Full Text] [Related]
35. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
[TBL] [Abstract][Full Text] [Related]
36. N-myc amplification and cell proliferation rate in human neuroblastoma.
Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
[TBL] [Abstract][Full Text] [Related]
37. CD44 is an independent prognostic factor in early-stage cervical cancer.
Speiser P; Wanner C; Tempfer C; Mittelböck M; Hanzal E; Bancher-Todesca D; Gitsch G; Reinthaller A; Kainz C
Int J Cancer; 1997 Apr; 74(2):185-8. PubMed ID: 9133453
[TBL] [Abstract][Full Text] [Related]
38. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.
Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Ambros P; Ambros I; Ladanyi M; Eddy J; Bonilla MA; Gerald W
Eur J Cancer; 1997 Oct; 33(12):2117-20. PubMed ID: 9516865
[TBL] [Abstract][Full Text] [Related]
39. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
[TBL] [Abstract][Full Text] [Related]
40. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]